BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 26773284)

  • 1. The role of microRNA in myelodysplastic syndromes: beyond DNA methylation and histone modification.
    Milunović V; Mandac Rogulj I; Planinc-Peraica A; Bulycheva E; Kolonić Ostojić S
    Eur J Haematol; 2016 Jun; 96(6):553-63. PubMed ID: 26773284
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epigenetic alterations and microRNAs: new players in the pathogenesis of myelodysplastic syndromes.
    Vasilatou D; Papageorgiou SG; Dimitriadis G; Pappa V
    Epigenetics; 2013 Jun; 8(6):561-70. PubMed ID: 23760524
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetic and epigenetic pathways in myelodysplastic syndromes: A brief overview.
    Jhanwar SC
    Adv Biol Regul; 2015 May; 58():28-37. PubMed ID: 25499150
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetics factors associated with myelodysplastic syndromes.
    Macedo LC; Silvestre AP; Rodrigues C; de Alencar JB; Zacarias JM; Ambrosio-Albuquerque EP; Sell AM; Visentainer JE
    Blood Cells Mol Dis; 2015 Jun; 55(1):76-81. PubMed ID: 25976472
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Somatic mutations and epigenetic abnormalities in myelodysplastic syndromes.
    Itzykson R; Kosmider O; Fenaux P
    Best Pract Res Clin Haematol; 2013 Dec; 26(4):355-64. PubMed ID: 24507812
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular mechanism of microRNA involvement in genesis of myelodysplastic syndrome and its transformation to acute myeloid leukemia.
    Liao R; Xu Y; Chen M; Chen X; Zhan X; Sun J
    Hematology; 2013 Jul; 18(4):191-7. PubMed ID: 23321417
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetic and Epigenetic Drug Targets in Myelodysplastic Syndromes.
    Stankov K; Stankov S; Katanic J
    Curr Pharm Des; 2017; 23(1):135-169. PubMed ID: 27697023
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epigenetic regulation in myelodysplastic syndromes: implications for therapy.
    Vigna E; Recchia AG; Madeo A; Gentile M; Bossio S; Mazzone C; Lucia E; Morabito L; Gigliotti V; Stefano LD; Caruso N; Servillo P; Franzese S; Fimognari F; Bisconte MG; Gentile C; Morabito F
    Expert Opin Investig Drugs; 2011 Apr; 20(4):465-93. PubMed ID: 21381982
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of DNA methylation in the pathogenesis and treatment of myelodysplastic syndromes.
    Khan H; Vale C; Bhagat T; Verma A
    Semin Hematol; 2013 Jan; 50(1):16-37. PubMed ID: 23507481
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Deregulated microRNA expression and its pathogenetic implications for myelodysplastic syndromes.
    Kuang X; Chi J; Wang L
    Hematology; 2016 Dec; 21(10):593-602. PubMed ID: 27357100
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gene methylation in gastric cancer.
    Qu Y; Dang S; Hou P
    Clin Chim Acta; 2013 Sep; 424():53-65. PubMed ID: 23669186
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overexpression of the EZH2, RING1 and BMI1 genes is common in myelodysplastic syndromes: relation to adverse epigenetic alteration and poor prognostic scoring.
    Xu F; Li X; Wu L; Zhang Q; Yang R; Yang Y; Zhang Z; He Q; Chang C
    Ann Hematol; 2011 Jun; 90(6):643-53. PubMed ID: 21125401
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epigenetics of myelodysplastic syndromes.
    Itzykson R; Fenaux P
    Leukemia; 2014 Mar; 28(3):497-506. PubMed ID: 24247656
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The molecular pathogenesis of the myelodysplastic syndromes.
    Pellagatti A; Boultwood J
    Eur J Haematol; 2015 Jul; 95(1):3-15. PubMed ID: 25645650
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Advance of studies on microRNA and myelodysplastic syndrome].
    Yang YJ; Li X
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Aug; 19(4):1079-82. PubMed ID: 21867648
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The molecular basis and clinical significance of genetic mutations identified in myelodysplastic syndromes.
    Zhang L; Padron E; Lancet J
    Leuk Res; 2015 Jan; 39(1):6-17. PubMed ID: 25465125
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of histone methyltransferase EZH2 in myelodysplastic syndromes.
    Xu F; Li X
    Expert Rev Hematol; 2012 Apr; 5(2):177-85. PubMed ID: 22475286
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Epigenetic alterations in myelodysplastic syndromes].
    Xu F; Li X
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Apr; 18(2):531-5. PubMed ID: 20416204
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression, Regulation and Function of microRNA as Important Players in the Transition of MDS to Secondary AML and Their Cross Talk to RNA-Binding Proteins.
    Bauer M; Vaxevanis C; Heimer N; Al-Ali HK; Jaekel N; Bachmann M; Wickenhauser C; Seliger B
    Int J Mol Sci; 2020 Sep; 21(19):. PubMed ID: 32992663
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetics of myelodysplastic syndromes: new insights.
    Graubert T; Walter MJ
    Hematology Am Soc Hematol Educ Program; 2011; 2011():543-9. PubMed ID: 22160087
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.